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ABSTRACT 
CELL PENETRATING PEPTIDE AMPHIPHILE INTEGRATED LIPOSOMAL 
 
    SYSTEMS FOR ENHANCED DELIVERY OF CARGO TO TUMOR CELLS 
 
Murat Kılınç 
M.S. in Materials Science and Nanotechnology 
Supervisor: Assoc. Prof. Ayşe Begüm Tekinay 
August, 2013 
 
Liposomes have been extensively utilized as effective nanocarriers due to their enhanced 
solubility, higher stability and greater ability to facilitate the slow release of encapsulated 
drugs compared to free drug administrations. Liposomes are also preferred as drug vectors 
due to their non-toxic nature, biodegradability and structural resemblance to the cell 
membrane. However, their low internalization efficiencies pose an important challenge for 
their use in drug delivery applications. Internalization issues inherent in many liposomal 
systems can be circumvented by the use of cell penetrating peptides, which non-covalently 
attach on the liposome surface and greatly enhance liposomal uptake in a receptor- and 
charge-dependent manner. 
 
In this study, we examined the liposomal dynamics effected through the integration of an 
amphiphilic cell penetrating peptide into a simple liposome system. Peptide amphiphiles 
with a cell penetrating arginine-rich domain were incorporated into liposomal membranes 
formed by negatively charged dioleoylphosphoglycerol (DOPG) phospholipids in the 
presence of cholesterol. Throughout the present study, we sought to analyze the effect of 
peptide incorporation on (a) the physical characteristics, such as size, surface potential 
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and membrane polarity, of the liposomal membrane, (b) the alterations in the 
encapsulation and delivery mechanisms of hydrophilic (Rhodamine B) and hydrophobic 
(Nile Red) drug models and (c) the enhancement of therapeutic capability in liposomes 
loaded with the drugs Doxorubicin-HCl and Paclitaxel. Our results revealed that the 
modification of liposomes by cell penetrating peptide amphiphiles results in the 
improvement of cargo delivery and the enhancement of the therapeutic effects of the anti-
cancer drugs Doxurubicin and Paclitaxel. 
 
Keywords: Cell Penetrating Peptide, Liposome, Cancer, Drug Delivery 
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ÖZET 
LİPOZOMLARIN HÜCRE DELİCİ PEPTİTLERLE MODİFİYE EDİLİLEREK 
ANTİKANSER İLAÇ GÖNDERİMİNİN GELİŞTİRİLMESİ 
 
Murat Kılınç 
Malzeme Bilimi ve Nanoteknoloji Programı, Yüksek Lisans 
Tez Yöneticisi: Assoc. Prof. Ayşe Begüm Tekinay 
Ağustos, 2013 
 
İlaçlara kattığı yüksek çözünürlük, stabilite ve zaman salınımı gibi özellikleri olması 
itibariyle liposozmlar etkili nano taşıyıcılar olarak yaygınca kullanılmaktadır. Toksik etki 
göstermemeleri, biyobozunurluğu ve hücre zarına benzer yapıda olmaları da lipozomların 
tercih edilmesindeki diğer sebeplerdir. Buna rağmen lipozomların hücre içine alınımının 
kısıtlı olması, lipozomların ilaç taşıyıcısı olarak kullanımında önemli sorunlar teşkil 
etmektedir. Bu durumun üstesinden gelme amacıyla lipozomları reseptör ve yük bağıntılı 
işlev gören hücre delici peptitlerle modifiye edip lipozomların hücre içine girişini 
desteklemek kayda değer bir stratejidir. 
 
Bu çalışmada, liposomları tek adımda modifiye eden bir sistem geliştirilmiş olup,  entegre 
olan amfifilik hücre delici peptitlerin lipozomların etkinliği üzerindeki rolü test edilmiştir. 
Arjinin miktarı itibariyle zengin hücre delici bölümü ve hidrokarbon zincirine sahip hücre 
delici peptitler DOPG ve kolesterolden oluşan eksi yüklü lipozomlara entegre edilmiştir. 
Çalışmada modifiye edilmiş lipozomların (a) boyut, yüzey potansiyeli ve zar polaritesi 
gibi fiziksel özellikleri, (b) hidrofilik Rhodamin B ve hidrofobik Nile Red gibi ilaç 
modellerinin enkapsülasyon ve iletim etkinliği, (c) Paclitaxel ve Doxurobicin-HCl gibi 
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anti kanser ilaçlarla yüklenmesi sonrası terapütik etkinliği araştırılmıştır. Sonuçlar 
ışığında amfifilik hücre delici peptitlerle kovalent bağ olmaksızın modifiye edilmiş 
lipozomların ilaç iletimi yönünden daha iyi olup, anti kanser ilaçlarla yüklendiğinde 
terapütik etkinliğini arttığını göstermiştir. 
 
Anahtar Kelimeler: Hücre delici peptitler, Lipozomlar, Kanser, İlaç İletimi 
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CHAPTER 1  
INTRODUCTION 
1.1 CANCER 
The World Health Organization (WHO) lists cancer as the second most prevalent cause of 
death in developed countries, after cardiovascular diseases. In the developing world, 
cancer is ranked as the third most common lethal medical condition. In addition to being a 
terminal illness, cancer poses an immense economic and psychological burden on the 
affected and their families. Factors like aging, unhealthy lifestyles (malnutrition, smoking 
etc.) and pollution increase the incidence and mortality rates of cancer. By 2020, 16 
million new cases are estimated to emerge around the world. Due to the frequency of 
incidence, high mortality rates and difficulty of treatment associated with many cancers, 
efficient treatment strategies against this disease are urgently necessary.  
 
1.2 STRATEGIES FOR CANCER TREATMENT 
Cancer can be managed with variety of options, such as cytoreductive surgery, 
radiotherapy, chemotherapy and immunotherapy. The selection among these therapies 
depends on parameters such as the type (e.g. whether the tumor in question is metastatic), 
location, size and structure of the malignant tumor. In all treatments, the primary goal is 
the removal of all cancerous cells with minimum collateral damage to the native, healthy 
body tissue. However, current treatment technologies are rarely capable of eliminating all 
malignant cells while keeping normal cells perfectly healthy. When tumors are 
structurally distinct and less invasive, or located in non vital organs, it may be possible to 
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remove all cancer tissue from body by surgery. But this is not a common case, since many 
types of malignancies either occur in vital organs or have a natural tendency to invade 
vital tissues and form malignant structures that cannot be separated from native tissue by 
mechanical means. In addition, cancer cells can spread to very distant tissues via 
metastasis, or may recur in the same location and necessitate the resumption of treatment . 
Chemotherapeutic agents and radiotherapeutic applications are often capable of 
eliminating cancer cells to a greater extent than invasive surgery, but also cause systemic 
side effects and result in the death of healthy cells. Immunotherapy is not associated with 
particularly severe side effects, yet it is also slow to act and provides enough time for 
tumor cells to evolve defensive mechanisms.   
 
A variety of cancer treatment options, each with their distinct sets of advantages and 
disadvantages, are available for specific types of cancers in specific degrees of progress. 
We will discuss these treatment options briefly to develop a broad understanding of cancer 
treatment before detailing advanced anticancer drug delivery strategies.   
 
1.2.1 Cytoreductive Surgery 
Local tumors with non-invasive characteristics can be ectomized by basic surgery.  This 
procedure involves the removal of either the tumor tissue or the entire organ in which the 
tumor is nested. Removal of excessive prostate tissue in prostate cancer and mastectomy 
in breast cancer are examples of such surgical procedures. The main concern in anti-
cancer surgeries is the elimination of leftover cancer cells on the tumor site. Since cancer 
cells reproduce at rates much greater than their healthy equivalents, even a single 
remaining malignant cell may well end up forming a new tumor.  
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Against metastatic cancers, surgery can only provide short term relief and cannot serve as 
a conclusive treatment. Even if the majority of the tumor mass is removed from its initial 
location, surviving cancer cells frequently establish metastatic tumors throughout the body 
by traveling through blood and lymph streams. The development of these new tumors 
almost inevitably necessitates further treatment.  
 
1.2.2 Radiotherapy 
Cancer cell irradiation is an effective way to kill target cells. In this procedure, radio 
waves are focused on target tissues and cancer cells are exposed to ionizing radiation. The 
main rationale of this treatment is to disrupt cell metabolism via radiation-induced DNA 
damage. When the cell physiology is disrupted, survival and division rates decrease and 
the target tissue shrinks in mass. The main problem associated with radiotherapy is the 
exposure of healthy cells to ionizing radiation. Compared to tumor cells, healthy cells 
have more efficient DNA repair mechanisms, and are much more resistant to radiation. 
However, the failure to repair a single incident of oncogenic mutation may result in the 
occurrence of cancer in any tissue exposed to radiation therapy. Furthermore, as with 
surgery, radiotherapy alone is not a sufficient treatment method against metastatic tumors. 
Local tumors can be destroyed efficiently, yet new treatments will be necessary when 
metastasized cancer cells form new tumor masses throughout the body.  
 
1.2.3 Immunotherapy 
Cancer cells can be eliminated by manipulating the immune system to fight against tumor 
cells. For this purpose, cytokines and interferons are frequently utilized to enhance the 
immune alertness of body. Since cancer cells divide often and have weak DNA repair 
mechanisms, they are likely to produce mutated antigens that can be recognized when 
18 
 
immune alertness is high. When these tumor antigens are recognized by T cells and 
natural killer cells, the tumor tissue is rapidly invaded by the immune system and 
apoptotic signals are produced to initiate cell death in tumor cells.  
 
Cell based therapies, which involve the recruitment or priming of immune cells against 
malignant tumors, are also among available methods. Perhaps the most striking example 
of such a treatment approach is dendritic cell therapy, which utilizes the priming of these 
cells against tumor antigens.[1-2] In this procedure, isolated dendritic cells are co-cultured 
with tumor cells and primed against tumor antigens. When dendritic cells are transplanted 
to the patient, they activate the immune system against cancer cells, which eventually 
leads tumor shrinkage. This procedure is capable of increasing life expectancies by up to 
several years, even with conditions normally associated with very poor prognoses, such as 
pancreas cancer.  
 
Overall, immunotherapy is an efficient way to manage cancer, yet there are several 
weaknesses associated with it. First, a boost to the immune system may trigger the 
development of autoimmune disorders, which will harm healthy tissue along with cancer 
cells. Further, cancer cells are capable of rapidly adapting to hostile conditions and 
surviving cells may be able to escape from enhanced immune surveillance by producing 
new antigens. These survivors can then continue to divide and restore the tumor to its 
original size.  
 
1.2.4 Chemotherapy 
Chemotherapy is use of cytotoxic chemical substances against cancer cells, and primarily 
relies on drugs that display more pronounced effects against frequently dividing cells. By 
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interfering with specific cellular processes (e.g. DNA replication or microtubule 
dynamics), these drugs are able to cause cytotoxic damage or trigger growth inhibition. 
For example, drugs like Doxorubicin, Cisplatin and Daunomycin intercalate with DNA to 
impair transcription and replication.[3-4] Other drugs, like Paclitaxel, Taxanes and 
Epothilones, inhibit the movement of microtubules, which is essential for cell division.[5-
6] These drugs share the common ability to block the cell cycle at a certain point, 
triggering a cell cycle arrest that will eventually result in cell death.  Since such drugs are 
administered directly into the bloodstream, they can reach every part of body, which 
renders them highly effective against metastatic tumors.  
 
While chemotherapeutics are effective against fast-dividing cancer cells, they are also 
associated with severely detrimental side effects due to the considerable cytotoxicity they 
exhibit against healthy cells. Since chemotherapeutics are widely distributed throughout 
the body, they are capable of significantly altering the physiology of systems with high 
cell turnovers, usually for the worse. Disruption of hematopoietic stem cell division and 
adult neurogenesis are examples of side effects caused by these treatments, which are 
much more severe than the hair and nail losses associated with other treatments. In order 
to reduce side effects and increase treatment efficiency, sophisticated drug administration 
methods need to be developed. These strategies must focus on delivery vehicles with 
accurate tumor targeting and effective internalization capacities. As the focus of the 
present work is the delivery of chemotherapeutic agents using advanced nanocarrier 
systems, the next section will be devoted to an in-depth discussion of nanocarrier-based 
drug delivery systems to further detail the opportunities and restrictions this novel 
nanomedical approach presents.  
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1.3 NANOSCALE DELIVERY OF ANTICANCER AGENTS 
The uptake inefficiency, misdistribution and metabolic interference of therapeutic agents 
such as pharmaceuticals, peptides or nucleic acids, continue to represent major challenges 
in their medical applications. The cell membrane acts as an impermeable barrier to a wide 
range of these therapeutic substances and, by blocking their entry into cells, prevents them 
from manifesting their physiological impact. For many years it has been a great challenge 
to increase the transportation rate of therapeutics through the cell membrane. To this end, 
the discovery of liposomes around half a century ago served as an attractive opportunity 
for pharmaceutical applications. Later still, natural and synthetic cell penetrating peptides, 
which enhance the translocation of materials across the cell membrane, were discovered, 
and this finding opened new possibilities in biomedical research.  
 
Integration of nanotechnological applications into medical research revolutionized the 
area of cancer therapeutics. A variety of nanocarrier systems can be designed to accurately 
deliver drugs into target cells with little to no loss of efficiency. The ideal nanoscale 
delivery agent ensures that the anticancer drug is accurately localized in the tissue(s) of 
interest without loss of function or efficiency.[7] In order to achieve the greatest 
therapeutic efficiency, nanocarriers should be able to a) improve the half-life of the drug 
cargo by protecting it from degradation b) prevent non-specific localization and action of 
drugs c) prevent the premature escape of the drug from circulation d) improve the 
absorption of the drug by the target tissue and/or e) improve the cellular uptake of the 
drug.[8] An ideal nanocarrier should be capable of fulfilling all of these criteria. 
 
Many parameters may alter the effectiveness of nanocarrier dynamics. The size of 
nanoparticles may determine their localization patterns in the body: Small particles, for 
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example are capable of crossing biological barriers easily and can be excreted quickly by 
kidneys.[9] Surface charge is another important criterion, and positively charged 
nanoparticles in particular may have a higher capacity for cellular uptake due to their 
affinity for the negatively charged cell membrane.[10] On the other hand, using 
nanoparticles with negative surface charges can prevent non-specific internalization 
events and improve selectivity when utilized alongside targeting residues. Another 
important feature of nanocarriers is surface hydrodynamics. Nanocarriers with 
hydrophobic surfaces tend to aggregate and are eventually captured by immune cells. 
Hydrophilic polymer coats therefore improve solubility and circulation times.[11]   
 
In addition to operational requirements, biocompatibility and biodegradability are key 
properties of any nanoscale agent in internal medicine.[7] The carrier has to be 
metabolized into smaller nontoxic components that can be cleared from circulation by 
means of renal excretion or further metabolization. Therefore, both composition and size 
of nanocarriers are important parameters. For instance, liposomes are perfectly 
biocompatible since they consist of natural or synthetic lipids that can easily be 
metabolized. Metal-based carrier systems, such as gold and iron oxide nanoparticles, 
cannot be metabolized by cells and have a size-dependent tendency to accumulate in 
various body parts.[12] Thus, in the case of inorganic nanoparticles, it is necessary to 
adjust particle sizes such that renal excretion is feasible. As stated earlier, the size of the 
nanocarrier is important in crossing biological barriers, such as the blood brain barrier or 
the nephrons of the kidney.[9] 
 
Despite displaying significant advantages over free drugs, current nanocarrier systems are 
far from having ideal features all across the board. There are various types of nanocarrier 
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systems with individual strengths and weaknesses. In this section, we will review these 
nanocarrier systems to develop a broader understanding of nanomaterial applications on 
cancer therapeutics. 
 
1.3.1 Polymer Based Nanocarriers 
Polymeric nanoparticles are sub-micron level carriers that can be synthesized from natural 
or synthetic polymers. Depending on the polymer type and synthesis procedure, particles 
with different sizes, shapes and encapsulation capacities can be obtained. The critical 
feature of polymer based nanoparticles is that they are suitable for surface modifications 
to facilitate tumor targeting or controlled release.[13] An abundance of end groups on the 
nanocarrier surface allows the efficient chemical modification of these nanoparticles with 
various targeting or penetration-enabling residues. In order to control the release 
dynamics, drugs can be absorbed or encapsulated within the polymer based structure. 
Structural changes within the drug-carrier complex may also alter treatment 
efficiency.[14]  
 
Polymers like PLGA, PLA, chitosan, guar gum and gelatin are commonly used for 
nanocarrier fabrication. Various methods of synthesis and modification can be utilized to 
improve drug carriage and facilitate targeted therapy. For instance, a study by Sharma et 
al., reports guar gum nanoparticles functionalized by folate and methotrexate to 
specifically target colon cancer tissue.[15] Like most polymer based nanocores, guar gum 
particles have an abundance of functional groups amenable for modification, which were 
utilized for the attachment of a great number of targeting residues. In vivo studies done by 
this group confirmed the preferential uptake of nanoparticles to the large intestine. In 
another study, paclitaxel loaded gelatin nanoparticles were used for the intravascular 
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treatment of bladder cancer.[16] It is notable that gelatin based nanoparticles displayed 
targeting abilities without any modification. Since tumors produce high amount of 
unstructured collagen, gelatin based materials may preferentially attach to cancerous 
tissue via strand invasion. In this particular study, nanoparticles were administered to the 
bladder itself and the nanocarriers were thus protected from proteolytic destruction, which 
would have happened if they were given directly into the bloodstream. 
 
1.3.2 Inorganic Nanospheres 
A large range of inorganic nanocarrier systems can be used for the delivery of therapeutics 
such as DNA, proteins and chemotherapeutic agents. However, inorganic nanoparticles 
have to be modified with biological (or at least biofunctional) materials to operate safely 
and efficiently. Additionally, these modifications have to improve the interaction between 
the nanocarrier and the therapeutic agent in order to increase drug stability and prevent 
premature leakage.[17] Many inorganic nanocarrier materials are inert, display low 
solubilities and cannot be efficiently metabolized by body. Surface modification of these 
particles must be adjusted depending on the material type, therapeutic agent and target 
tissue. For instance, gold nanoparticles are frequently modified with thiol groups, while 
carbon based nanostructures are commonly functionalized with carboxyl groups.[17] 
 
In order to produce efficient and clinical grade inorganic nanocarriers, two main problems 
must be solved. First, a suitable chemical interaction must occur between the nanocarrier 
and the therapeutic agent. Drug-carrier interactions have to be in optimal levels to provide 
controlled release. Interactions between nanocarriers and drugs are mainly mediated by 
hydrophobicity or electrostatic forces.  Since inorganic nanocarriers generally have dense 
cores, they cannot be used for the encapsulation of therapeutics. As such, surface 
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modifications must be performed to facilitate the adsorption of therapeutic agents onto the 
inorganic core surface. For instance, in a study done by Kneuer et al. , silica based 
nanoparticles were modified with N-(2-aminoethyl)-3-aminopropyltrimethoxysilane or N-
(6-aminohexyl)-3-aminopropyltrimethoxysilane to create a positive surface charge on the 
silica surface.[18] This surface, due to its high positive charge, was able to adsorb DNA 
molecules and form a DNA carrier system.  
 
The second challenge associated with inorganic nanospheres is to attach a variety of 
functional groups to improve therapeutic dynamics of the drug-carrier complex without 
compromising the core-drug interaction. Improvements on cellular penetration and 
targeting capabilities are common objectives for the secondary modification of 
nanocarriers. For example, it has been shown that magnetic nanoparticles modified with 
polyethylene glycol and folic acid display enhanced internalization by breast cancer cells 
compared to nanoparticles modified with only polyethylene glycol.[19] In another study, 
iron oxide nanoparticles were modified with arginine-glycine-aspartate (RGD) peptide 
and chlorotoxin, which target several types of integrins and matrix metalloproteins that 
are overexpressed in variety of cancer tissues.[20] By doing so, they were able to achieve 
cancer-specific targeting capacity and tumor shrinkage.  
 
1.3.3 Liposomes 
Liposomes are biomimetic delivery systems that have been used to administer various 
therapeutic and imaging agents. Compared to free drugs, they are significantly 
advantageous in terms of pharmacokinetics, efficiency and management of side effects. In 
addition to their innately superior physicochemical properties, they can be modified for 
specific purposes such as tissue targeting or improved cell penetration. For these reasons, 
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liposomal chemotherapeutics have been used as advanced anti cancer agents for several 
decades. There are many forms of liposomal chemotherapeutics that are already being 
used by clinics, such as Doxil and Marqibo.[21-22] Many more such drugs, like MBP-426 
and ThermoDox, are in development and will soon be ready for clinical trials.[23-24] 
Since liposomes are the main focus in this thesis, the following sections will encompass 
an extensive review of liposomal drug delivery. We will first detail the physicochemical 
properties of liposomes, and then continue with their surface modification potential and 
anti cancer applications.  
 
1.3.3.1 Physical Properties of Liposomes 
Liposomes are nanosized vesicular structures artificially produced from natural or 
synthetic lipids and cholesterol. When combined under suitable conditions, lipids align to 
form bilayered spherical structures in water, which eventually stabilize as liposomal 
vesicles. Since lipids have both hydrophobic and hydrophilic sites, they are highly 
disposed towards a configuration where their hydrophilic regions face outwards and their 
hydrophobic sections collapse together. 
 
Liposomes can be produced in various forms. Parameters like size, lamellarity and 
composition significantly influence various features, such as stability, drug containment 
capacity, and solubility. If need be, synthesis conditions can be altered to adjust these 
properties. Liposomes can be multilamellar or unilamellar. Briefly, multilamellar 
liposomes have multiple concentric bilayers within each other while unilamellar 
liposomes consist of a single lipid bilayer. Unilamellar liposomes are also classified 
further with respect to their size. Liposomes ranging from 20-40 nm in diameter are 
classified as small unilamellar vesicles, while these that with 40-80 nm diameter sizes are 
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called medium unilamellar vesicles.[25] Any liposomal vesicle larger than 100 nm is 
considered a large unilamellar vesicle. Multilamellar liposomes tend to be larger, since 
larger volumes are necessary to build up their concentric series of bilayers. Figure 1 
demonstrates the basic structural differences between unilamellar and multilamellar 
liposomes. 
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Figure 1 Physical properties of unilamellar and multilamellar liposomes. A. Schematics of 
basic lipids and a lipid bilayer. B. Schematic of unilamellar liposomes. C. Schematic of 
multilamellar liposomes. D. Cryo-TEM image of unilamellar liposomes. Adopted from 
Battersby et al.[26] E. Cryo-TEM image of a multilamellar liposome. Image acquired from 
vironova.com. Scale bars are 50 nm. All schematics adopted were from encapsula.com. 
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Phosphatidyl Glycerol (PG), Phosphatidyl Serine (PS) and Phosphatidyl Choline (PC) are 
natural lipids found in such products as animal fat and eggs, while lipids like Distareol 
Phosphatidyl Choline (DSPC), Dipalmitoyl Phosphatidyl Choline (DPPC), Dioleoyl 
Phosphatidyl Glycerol (DOPG) and Dipalmitoyl Phosphatidyl Serine (DPPS) are 
synthesized artificially. 
 
These lipids differ in size, shape and/or charge, and provide different physicochemical 
characteristics to the liposomes they form. These characteristics are significant enough to 
alter the native behavior of these liposomes throughout the body. A study done by 
Gabizon et al. clearly demonstrates this effect.[27] In this study, researchers prepared a 
variety of liposomes with similar physical properties yet different lipid compositions. PG-
PC, PG-DSPC, DPPG-DSPC, HPI-DSPC and GM-DSPC liposomes were prepared in the 
presence of cholesterol, and the biodistribution of liposomes were analyzed following 
intravenous administration. After 24 h of exposure, high accumulations of PG-PC-Chol, 
GM-DSPC-Chol and DPPG-DSPC-Chol liposomes were observed in liver and spleen. In 
terms of passive tumor targeting, HPI-DSPC-Chol and GM-DSPC-Chol liposomes were 
superior compared to others.  
 
In addition to phospholipids, cholesterol is a staple as a liposome constituent. Cholesterol 
has no capacity to form a bilayer or vesicular structure by itself, and yet has drastic effects 
on liposome properties when used in conjunction with phospholipids. The addition of 
cholesterol improves the rigidity and stability of the vesicle membrane and reduces the 
permeability of water-soluble molecules.[25] The use of cholesterol is therefore clearly 
advantageous, especially when the drug load is hydrophilic and leaky. 
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Effects of cholesterol content to liposome structure were extensively studied by Kirby and 
colleagues.[28] In this study, the stability of negatively or positively charged small 
unilamellar liposomes with varying cholesterol contents was tested both in vivo and in 
vitro. Cholesterol rich liposomes were found to be capable of remaining stable in both 
circulation and in vitro environment regardless of their surface charge. In contrast, 
cholesterol-poor and cholesterol-free liposomes degraded very quickly when exposed to 
whole blood, plasma or serum. When injected intraperitoneally, high cholesterol, neutral 
charged liposomes demonstrated the greatest stability. 
 
Beside its ability to provide stability to the supramolecular structure of liposomes, 
cholesterol is also capable of improving the stability of the cargo. Research by Lee et al. 
demonstrated that liposomes containing high amounts of cholesterol are more efficient in 
terms of stabilizing retinol, a lipophilic compound.[29] Two properties of cholesterol 
allow this molecule to increase drug stability. First, by bridging strong bonds between 
lipids, cholesterol prevents the leakage and eventual loss of cargo. In addition, by forming 
strong bonds with hydrophobic molecules, cholesterol further blocks the dissipation of 
material and acts as a stabilizing barrier against diffusible reactants from outside. 
 
1.3.3.3 Characterization of Liposomes 
The development of accurate quality assessment criteria for liposomes is crucial to enable 
the objective comparison between different liposome formulations. Since many 
physicochemical properties have vital roles in liposome dynamics, many properties have 
to be measured accurately to gain a thorough understanding of the liposome’s ability to 
deliver a given drug. The most important aspects of liposomes are their lamellarity, size, 
surface charge, encapsulation efficiency and release profile. In this section, we will review 
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why these characteristics are important, and how they can be quantified. 
 
Determination of Lamellarity: 
Lamellarity is an important factor on liposomal dynamics due to its influence on the 
encapsulation and release of drugs.[30] Additionally, after endocytosis, it is likely that the 
fate of the liposome and its contents is significantly affected by the number of lamellae. 
As such, an accurate analysis of lamellarity is crucial. 
 
Lamellarity can be measured with a variety of complex methods, such as NMR (by 
estimating intravesicular lipid content) and small angle x-ray scattering (by Fourier 
Transformation of scattered light, which will give the a probability distribution for the 
distances between electrons).[30] More direct and simple methods, such as freeze 
fractured TEM, can also be used for lamellarity analysis. In this technique, small amounts 
of sample are loaded into the imaging chamber, and freeze-shock is applied. Liposomes 
keep their morphology due to the high speed cooling, and can be imaged via electron 
microscopy. Acquired images can be analyzed and statistically consistent lamellarity rates 
can be obtained using this technique. 
 
Size Measurement: 
Size is an essential aspect of liposomes in clinical use. As mentioned previously, 
localization, longevity and fate of liposomes are heavily affected by size. There are 
several techniques available to calculate the exact size of, or make comparative size 
analyses between, liposomes. These include microscopy techniques and chromatographic 
methods.   
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Any microscopy technique that allows liposomes to maintain their size and shape can be 
used for size measurement. The most important concern in image-based size assessment 
methods is to keep liposomes from size and shape changes, which is usually accomplished 
by structurally fixing them prior to imaging. When this criterion is fulfilled, any method 
with proper resolution and magnification power can be used. As with lamellarity analysis, 
freeze fractured TEM can be used for the size assessment of liposomes. Other variations 
of electron microscopy systems, such as cryo-EM or EM with negative staining also 
provide the required information. Other than electron beam dependent systems, atomic 
force microscopy (AFM) is also used in liposome size assessment.[31-32] 
 
In addition to microscopy based methods, chromatographic techniques also can be applied 
in order to compare and quantify liposomal size. Size exclusion chromatography is an 
ideal method for the separation of materials with distinct sizes, including liposomes. 
HPLC with size exclusion chromatography is commonly utilized in order to separate 
liposomes and non encapsulated materials.[30] However, it must be kept in mind that 
liposomes may get stuck in column during the progress of this technique, which can 
render it difficult to retrieve them. Depending on the type of lipid and surface 
modification, the interaction between the separation column and liposomes may be strong 
enough to interfere with both size measurements and liposome retrieval. 
 
Determination of Surface Charge: 
Surface charge is one of the most important aspects of liposomes, and plays a crucial role 
in determining the solubility and cell-liposome interactions of any given drug delivery 
vesicle. It may be affected from a variety of parameters, such as the type(s) of lipid used, 
surface modifications and cargo. Particles with low surface charges tend to pull each other 
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and aggregate. When we consider the relatively large initial size of liposomes, in vivo 
aggregations may result in tremendous damage throughout the body. Particles with high 
surface charges can repel each other through electromagnetic interactions, and are 
therefore more likely to dissolve and diffuse than to aggregate.  
 
In order to quantify surface charge, zeta potential measurements can be performed. This 
approach relies on the detection of minute changes in light scattering patterns following 
the application of electromagnetic forces on the sample. The scattering pattern fluctuates 
much more with highly charged materials compared to neutral and low charged 
materials.[30] 
 
Encapsulation Efficiency: 
Liposomes cannot encapsulate all the cargo dissolved in preparation media. A fraction 
will remain in media, while rest is successfully loaded. The ratio between loaded and 
unloaded cargo is an important parameter that enables us to estimate the amount of cargo 
per carrier molecule. By doing so, it is possible to adjust treatment doses to utilize optimal 
concentrations of drug and carrier. The main principle underlying the calculation of 
encapsulation efficiency is to separate unloaded material from liposomes and quantifying 
fractions. This can be achieved through various methods. Liposomes can be filtered 
through membranes with small pores to obtain a solution that contains only the unloaded 
material. Liposome solutions can be dialyzed with a membrane of appropriate size. 
Liposome pellets can be destructed with detergents and the cargo encapsulated by 
liposomes can be exposed for subsequent measurement. Finally, size exclusion 
chromatography can be applied in order to separate the unloaded cargo from the 
liposomes.[33] After separation, the amount of loaded and unloaded material can be 
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measured via absorbance or fluorescence, depending on the nature of the subject material. 
 
Profiling Liposomal Release: 
Profiling release dynamics is a crucial effort to estimate the time dependent efficiency of 
the drug-carrier complex. Vesicles with high release rates are predisposed towards 
aggressive behavior in shorter periods of time. Liposomes with low release rates tend to 
provide a sustained long term effect. Release rates, and therefore therapeutic dynamics, 
are affected by various conditions such as pH and temperature. Considering these 
parameter in release profiling experiments allows researchers to further understand and 
predict the behavior of liposomes in the body. Release dynamics of liposomes can be 
determined using an appropriate dialysis method.[34] Briefly, after separating liposomes 
from unloaded cargo materials, liposomes are placed in a dialysis bag. As liposomes 
release their contents, the concentration of the subject material will be increased in the 
solution outside the membrane. By acquiring small aliquots from this solution, time-based 
changes in the concentration of the released material can be observed. As stated earlier, 
the precise procedure for concentration measurements depends on the nature of the subject 
material. This method can also be applied at different pH or temperature values to 
understand release dynamics in various environmental conditions. 
 
1.3.3.4 Functionalization of Liposomes 
Surface modification is an essential tool for the functionalization of liposomes for specific 
purposes. Site specific drug delivery is possible by using different combinations of surface 
modifications. A variety of materials, such as carbohydrates, inorganic polymers, proteins, 
peptides and metals, can be attached to liposome surfaces to improve liposomal efficiency 
with respect to a specific purpose. For instance, several polymers (such as PEG) can be 
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used to improve the stability of liposomes and extend their circulation times. Antibodies 
can be conjugated to facilitate target-specific attachment. Used alongside a series of 
magnetic tools, some metals (such as iron oxide) can be used for active targeting to a 
subject tissue. The use of peptides with specific affinities (such as cell penetrating 
properties) is another method to improve liposomal dynamics by enhancing cellular 
uptake. Figure 2 demonstrates schematics of various liposomal surface modifications and 
functions. In the next section, we will discuss several types of liposome modifications and 
the therapeutic benefits associated with each modification type.  
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Figure 2 Strategies for liposome modification. (Top) Liposome modification with hydrophilic 
non bioactive polymers is frequently used for passive tumor targeting. (Bottom) Modification 
with cell penetrating peptides improves cellular uptake and drug delivery. (Left) Modification 
with antibodies is utilized to achieve target-specific attachment. (Right) Modification with 
bioactive small molecules is utilized to achieve ligand specific active targeting. Image 
adopted form Paliwal et al.  [35] 
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1.3.4 Liposome Surface Modifications 
1.3.4.1 Antibodies 
As mentioned earlier, gene expression profiles of cancer cells are different from their 
healthy counterparts. In some cases, this difference in gene expression results in 
alterations in surface antigen productions. Changes in surface antigen populations, allows 
cancer cells to be targeted via specific antibodies, which can be anchored to the liposome 
surface. For example, it is known that many types of breast cancer cells overexpress 
HER2, which is a growth factor receptor located on the cell surface.[36] Overexpression 
of this antigen provides an appropriate immunologic target for drug delivery applications. 
Using various forms of immunoliposomes, many studies have reported efficient targeting, 
accumulation and multiple drug delivery to HER2 over expressing tumors.[37-41] Up to 
sixfold higher tumor accumulations were observed with liposomes modified with HER2 
antibodies compared to their non modified equivalents. 
 
Liposomal targeting by immunological modification can also be applied to other forms of 
cancer. A study done by Sapre et al. reported that the efficiency of immunoliposomes 
against human B cell lymphoma.[42] Cancerous human lymphoid B cells overexpressing 
the surface antigen CD19 were targeted via liposomes modified with anti-CD19. 
Following modification, researchers observed longer circulation times and higher 
cytotoxicities against these cancer cells in blood.  
 
Another modification strategy is to target the vascularization of tumors. Vascular 
Endothelial Growth Factor (VEGF) is the primary regulator of angiogenesis and the 
expression of VEGF receptor (VEGFR) generally corresponds to the level of 
vascularization in a specific tissue.[43] As cancer cells grow continuously and tend to 
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form bulk tumors, they must induce angiogenesis to remain connected with blood 
circulation. Therefore, solid tumors have to overexpress signals capable of inducing the 
neovascularization required. As stated above, the extent of VGEF signaling corresponds to 
the vascularization of a given tissue, and the components of this signaling pathway are 
therefore abundantly expressed in many solid tumors. Thus, it is reasonable to utilize 
targeting strategies involving materials with an affinity to VEGFR or VEGF itself. Many 
studies reported improvement in tumor localization and cytotoxicity following the use of 
VEGF targeting antibodies.[44-45]  
 
1.3.4.2 Small Molecules 
Small molecules displaying high affinities to cancer cells can be used for liposome 
modification and may facilitate tumor specific targeting. For example, folic acid plays a 
crucial role in DNA biosynthesis, cell division and other metabolic events.[46] As cancer 
cells divide and replicate continuously, many forms of cancer cells overexpress folate 
receptors. Since receptor expression patterns for cancer and healthy cells are different, the 
increased affinity between folate and its receptor in tumor cells can be used to achieve 
liposomal targeting. Several studies have demonstrated the in vivo and in vitro efficiency 
of liposomes modified with folic acid-PEG conjugations, and have found that folate-
modified liposomes increase cancer cell cytotoxicity while doing little to no damage to 
healthy tissues.[47-48]  
 
Estrogen is another small molecule that can be used to target some types of cancer cells. 
60-80 percent of all breast cancer cells overexpress estrogen receptor (ER).[49] As such 
conjugating estrogen to liposome surface is a reasonable approach for tumor recognition. 
Several studies utilized this approach to specifically target breast cancer cells.[50-51] A 
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study by Paliwal et al. reported the improvement of treatment efficiency following the 
estrogen modification of doxorubicin-loaded stealth liposomes on tumor cytotoxicity.[50] 
In vitro cytotoxicity of liposomes to ER positive and negative cells was studied 
comparatively along with in vivo biodistribution and tumor growth inhibition. Estrogen 
modified liposomes achieved higher cytotoxicity against ER positive cancer cells 
compared to non modified liposomes. In addition to improved cytotoxicity, estrogen 
modified liposomes demonstrated distinctively higher drug stability and better tumor 
accumulation, such that drug half life was 50% higher and tumor accumulation six fold 
higher in liposomes with estrogen modification compared to non modified ones. 
 
1.3.4.3 Proteins 
Several proteins have been found to be useful for the manipulation of anticancer 
pharmacodynamics in liposomes, antibodies and small molecules. The main principle 
behind protein-based modifications is similar to previously mentioned approaches. 
Modification with transferrin (TF) protein can be given as an example. TF is an iron 
binding glycoprotein that stabilizes ferric iron and facilitates endocytosis via TF receptor 
(TFR).[52] It has been previously reported to be overexpressed in several cancer types, 
being associated with metastasis in particular.[53] As such, TF can be used as a targeting 
moiety in order to improve the therapeutic effect of various drug delivery systems against 
TFR-overexpressing cancer cells. Yue et al. functionalized Paclitaxel loaded vesicles with 
TFR-recognition capabilities and characterized the resulting improvements in delivery 
pharmacodynamics.[54] They have demonstrated that, following TF modification, the 
functionalized liposomes accumulated earlier in tumor tissue, and facilitated a greater 
extent of tumor shrinkage. In another study, Wu et al. developed TF modified liposomes 
encapsulating multiple drugs and reported that TF modification could improve the uptake 
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and cytotoxicity of liposomes.[55]  
 
1.3.4.4 Sugars 
Several types of sugars can be used for liposome functionalization. For instance, various 
cancer types, such as stomach, colon, breast, ovarian cancers and leukemia, overexpress 
the hyaluronic acid (HA) receptor CD44.[56] Eliaz et al. reported improvements in the 
targeting capacity of in HA-modified liposomes against CD44-overexpressing cancer 
cells.[57] In this study, researchers demonstrated that HA modified liposomes could 
selectively bind to CD44-overexpressing cancer cell lines. When loaded with 
Doxorubicin, HA modified liposomes achieved significantly better delivery rates, such 
that IC50 value of nonmodified liposomes was around 175 fold higher compared to HA 
modified liposomes. Active targeting of CD44 by HA modification was also reported in 
several other studies.[58-60] 
 
1.3.4.5 Peptides 
Peptides can be used to modify liposomesfor a variety of purposes, such as targeting 
tumors or improving pharmacokinetics. Peptides are small chains of amino acids that 
display distinct and adjustable chemical properties depending on their sequences. Peptides 
are advantageous in surface modification applications since they are easy to synthesize, 
structurally stable and can be tailored to serve specific purposes. By using different 
peptide sequences, it is possible to achieve targeting or improved cell penetration. 
 
Integrins are cell surface proteins involved in homodimeric cell to cell interactions 
mediating attachment, migration and division, and have been popular target molecules for 
drug delivery applications.. It has been previously reported that several types of integrins 
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are overexpressed in cancer cells.[61] This difference in expression can be utilized for 
active tumor targeting purposes. Peptides with RGD motifs have an affinity for native 
integrin proteins and are frequently used as tumor targeting moieties. In one study, for 
instance, liposomes modified with PEG-RGD conjugates were shown to target angiogenic 
tumors better and enhance tumor shrinkage, demonstrating higher accumulation in the 
tumor site and greater cytotoxicity compared to non-modified liposomes.[62]  
 
In addition to targeting, a family of peptide sequences can be used to improve cellular 
uptake. These positively-charged sequences are called cell penetrating peptides (CPP), 
and display a high capacity to facilitate entry into cells, rendering them particularly useful 
for the effective delivery liposomes into cytosolic or nuclear compartments.Following the 
derivation of the CPP from Human Immunodeficiency Virus proteins (HIV), many 
unifying features of CPPs have been characterized, and both natural and artificial CPP 
sequences continue to to provide new strategies for drug delivery applications.[63] As cell 
penetrating peptides are the main focus of this thesis, they will be discussed separately in 
the following section. 
 
1.3.4.6 Cell Penetrating Peptides 
Many different approaches, such as viral vectors, nanoparticles and liposomes, have been 
used for the delivery of DNA, drugs or other agents into cells. However, these methods all 
invariably display a number of undesirable properties, ranging from immune reactivity to 
inefficiency of delivery. The discovery of cell penetrating peptides (CPP), which improve 
cellular internalization and endosomal escape of macromolecules, has allowed the 
development of new strategies for drug delivery. Due to their ability to facilitate cellular 
internalization, CPPs offer a substantial opportunity to improve cargo delivery into target 
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cells. Thus, CPPs are an important focus on gene and drug delivery studies. 
 
CPPs are short peptide sequences that mainly consist of positively charged amino acids. 
These low molecular weight, highly cationic peptides are rich in basic amino acids like 
arginine or lysine.[64] In addition to their charge, their penetration capacity is based on 
their sequence and target cell type, since compatible membrane-CPPs interaction is crucial 
to achieve efficient penetration.[65] 
 
CPPs are capable of entering into cells via receptor mediated and/or non receptor 
mediated mechanisms. Although the internalization mechanisms are not fully understood, 
the coexistence of different uptake types is frequently suggested.[66] Since CPPs mainly 
consist of cationic amino acids, electrostatic interactions are important for the 
transduction of CPPs (and their cargo) through the cell membrane.[67] In addition to 
electrostatic interactions, receptor mediated macropinocytosis and subsequent endosomal 
release also have primary roles in the accumulation of CPPs in the cytoplasm.[68] 
Coexistence of various internalization mechanisms may help explain the delivery 
efficiency of CPPs.    
 
Several different strategies have been developed to integrate CPPs on liposome surfaces. 
This integration can be facilitated either through the efficient linkage of CPPs with 
reactive residues on the surface, or via non-covalent integration, as we have achieved in 
our study. One commonly used approach is the addition of cysteine to the CPP sequence 
to facilitate the formation of strong disulphide bonds with liposome surface residues.[69] 
Spacer molecules are also used to connect CPPs and liposomes. In addition to the covalent 
linkage of CPPs and liposomes, CPPs can be integrated into the lipid bilayer by non 
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covalent interactions. In our study, we modified CPPs with a hydrophobic lauric acid, 
which is both chemically and structurally similar to fatty acid chains of membrane lipids. 
By doing so, we allowed the non covalent incorporation of our CPP during liposome 
formation, such that our modified CPPs were added to the structure of liposomes due to 
their similarity to the other lipids within the liposome matrix.   
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1.4 MOTIVATION AND GOALS 
Peptide amphiphiles (PA) possess both a bioactive “head group” and a lipid-like alkyl tail 
in one molecule, which renders them highly suitable for the functionalization of liposome-
based drug carrier systems. PAs can be designed and chemically synthesized with high 
yield and specificity and, more importantly, are easy to incorporate into liposomes without 
experiencing activity loss or requiring laborious chemical functionalization steps, 
primarily due to the amphipathic properties that they share with lipids.[64, 70] Here, we 
designed and incorporated a poly-arginine cell penetrating amphiphilic peptide segment 
into a liposomal system, and examined the integration of this arginine-rich peptide 
amphiphile into liposomes formed by negatively charged dioleoylphosphoglycerol 
(DOPG) phospholipid molecules in the presence of cholesterol. We aimed to elucidate the 
changes in the physical characteristics of the resulting liposomes in terms of size, surface 
potential and membrane polarity, and characterized their encapsulation capacities using 
hydrophilic and hydrophobic dyes Rhodamine B and Nile Red. After optimizing the 
encapsulation efficiencies of liposomes using fluorescent dyes, we then profiled the 
dynamics of liposome uptake. Furthermore, we investigated the possible augmentation of 
anti-cancer properties in known cancer drugs, doxorubicin-HCl and paclitaxel, loaded into 
cell penetrating peptide amphiphile-modified liposomes. This study not only analyzes the 
effect of peptide amphiphile integration on the physical properties of liposomes, but also 
discusses the in vitro therapeutic effect of peptide amphiphile integrated liposomes on 
MCF7 breast cancer cells in terms of cellular uptake and cytotoxicity.  
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CHAPTER 2  
CELL PENETRATING PEPTIDE MODIFICATION FOR IMPROVED LIPOSOMAL 
DELIVERY OF ANTI CANCER THERAPEUTICS  
This part of thesis is based on article “Cell Penetrating Peptide Amphiphile Integrated 
Liposomal Systems for Enhanced Delivery of Anticancer Drugs to Tumor Cells” Published in 
RSC Faraday Discussions 
 
2.1 INTRODUCTION 
Liposomes are vesicles with varying diameters and contain lipid bilayers surrounding 
aqueous compartments. The self-organization of lipid molecules into bilayer in aqueous 
environment through their amphipathic character is responsible for the formation of 
spherical vesicles. Liposomes have been considered as potential drug delivery agents for 
several decades due to their biocompatibility, biodegradability and their resemblance to 
cell membrane. They have a long history of use to improve the delivery of many 
therapeutics such as vaccines, antibiotics and anticancer drugs.[71] Hydrophobic materials 
can be incorporated into the lipid bilayer of liposomes, while hydrophilic components can 
be encapsulated within aqueous lumen. 
Liposomes happen to be reliable drug delivery vehicles due to the following properties: 
 They are biocompatible, biodegradable and similar to cell membrane which makes 
their administration safe.[72]  
 They increase the longevity of cargo which will be exposed to metabolic 
interference of humorous environment unless it is protected. 
 They can be modified for specific purposes with a wide spectrum of functional 
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materials.[73] 
 
Phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE) and 
dioleoyltrimethylammonium propane (DOTAP) are commonly used lipids which can be 
isolated from natural resources or produced synthetically. PC is used for preparation of 
uncharged liposomes while PG, PE or DOTAP are used to introduce charges. Liposomes 
ordinarily contain cholesterol to improve stability and prevent leakage of cargo.  
 
Various approaches have been practically used to functionalize liposomes including 
chemical coupling of lipid molecule and ligand of interest before liposome formation, 
covalent conjugation of biologically active segments to the liposome surface and non-
covalent association of liposome constituents.[74-75] Their versatile nature enables design 
of various functional liposomal systems decorated with a wide range of bioactive 
molecules such as antibodies, viral proteins, carbohydrates, peptides, aptamers, and 
vitamins for therapeutic delivery.[71, 76-77] The easiness of functionalization together 
with their extensive encapsulation capacity make them attractive tools for the 
development of systems which deliver the cargo to the target location with enhanced in 
vivo stability and circulation time. Besides their facile integration, the versatility of 
modifications enables diverse biofunctionality to the liposomal carrier.  
 
Amphiphilic peptides comprised of a bioactive peptide sequence and a hydrophobic 
segment have great potential for functionalization of liposomal carriers. They can be 
designed and chemically synthesized with high yield and specificity and more 
importantly, they can be easily incorporated into liposomes noncovalently due to their 
lipid-like amphipathic property with minimized activity loss or without laborious 
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chemical functionalization steps.[78-81] The easiness of functionalization together with 
their extensive encapsulation capacity make them attractive tools for development of 
carrier systems, which can deliver cargo to the target with enhanced in vivo stability and 
circulation time.[82] Besides their facile integration, the versatility of peptide sequences 
provides diverse biofunctionality to the liposomal carriers.  
 
The importance of cell penetrating peptides including HIV-Tat derived peptides, 
oligoarginines, and chimeric cell penetrating peptides have been emphasized in several 
works for delivery of therapeutic agents to target cells.[83-84] Arginine-rich peptides were 
also synthesized and investigated for enhanced cellular uptake efficiency by conjugating 
with large molecules such as fatty acids.[85] 
 
Herein, we designed and synthesized an arginine-rich, cell penetrating peptide amphiphile 
molecule and examined its integration into liposomal formulation of 1,2-dioleoyl-sn-
glycero-3-[phosphor-rac-(1-glycerol)] (DOPG) phospholipid in the presence of 
cholesterol. We studied size, surface potential, and membrane polarity of the resulting 
liposomes with and without peptide amphiphile incorporation. Encapsulation capacities of 
these carriers were examined by using hydrophilic and hydrophobic dyes, Rhodamine B 
and Nile Red, respectively. After optimization of the encapsulation efficiencies of 
liposomes, in vitro uptake profile and cytotoxicity of cancer drugs including Doxorubicin-
HCl and Paclitaxel entrapped in liposomes with and without peptide amphiphile 
molecules were examined on MCF7 human breast cancer cell line.  
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2.2 MATERIALS & METHODS 
2.2.1 Chemicals and Solutions 
Lipids: 
1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] (DOPG) was purchased from 
Avanti Polar Lipids and Cholesterol from AppliChem. 
 
Peptides: 
9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) protected amino 
acids, [4-[α-(2’,4’-dimethoxyphenyl)Fmoc-aminomethyl]phenoxy]acetamidonorleucyl-
MBHA resin (Rink amide MBHA resin), 2-(1H-Benzotriazol-1-yl)-1,1,3,3 
tetramethyluronium hexafluorophosphate (HBTU) and  Lauric acid were purchased from 
NovaBiochem, ABCR and Merck. Piperidine, Acetic anhydride, Dichloromethane (DCM) 
and Dimethylformamide (DMF), N,N-diisopropylethylamine (DIEA), trifluoroacetic acid 
(TFA) : triisoproplysilane (TIS) were purchased form Sigma. 
 
Cell Culture Reagents: 
Dulbecco’s Modified Eagle Medium (DMEM), Penicillin/streptomycin (PS) antibiotic 
combination and fetal bovine serum (FBS) were purchased from Invitrogen Gibco.  
 
Liposome Contents: 
Anticancer drugs Doxorubicin-HCl (DOX) and Paclitaxel (PTX) were acquired from 
Applichem. Our tracking materials, Nile Red (NR) and Rhodamine B (RHB) were 
purchased from Alfa Aesar. 
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2.2.2 Peptide Synthesis and Characterization 
C12-PPPPRRRR-NH2 peptide amphiphile was constructed on MHBA Rink Amide resin. 
Amino acid couplings were performed with 2 equivalents of Fmoc protected amino acid, 
1.95 equivalents of HBTU and 3 equivalents of DIEA in DMF for 3 h. Fmoc deprotections 
were performed with 20% piperidine/DMF solution for 20 min. Cleavage of the peptides 
from the resin was carried out with a mixture of TFA:TIS:H2O in the ratio of 95:2.5:2.5 
for 2 h. Excess TFA was removed by rotary evaporation. The remaining viscous peptide 
solution was treated with ice-cold diethyl ether and the resulting white pellet was freeze-
dried. The peptide amphiphiles were identified and analyzed by reverse phase HPLC on 
an Agilent 6530 accurate-Mass Q-TOF LC/MS equipped with an Agilent 1200 HPLC. An 
Agilent Zorbax SB-C8 4.6 mm x 100 mm column was used as stationary phase and 
water/acetonitrile gradient with 0.1% volume of formic acid was used as mobile phase to 
identify peptide amphiphile. 
 
2.2.3 Liposomes 
2.2.3.1 Liposome Preparation 
Liposomes were prepared via curvature tuned preparation method reported previously.[86] 
50 mg of DOPG and Cholesterol combination was directly rehydrated in PBS buffer (10 
mM, pH 7.4, 3% glycerol, with cargo material) at 65 ⁰C under nitrogen supply while the 
mixture was continuously stirred. Further, solution was treated with a rapid pH jump (pH 
7.4→pH 11 →pH 7.4) continuing with an equilibrium period of 25 min, where lipid 
clusters curl into encapsulating nanosized liposomes. The resulting liposomes were 
purified using a G50 sephadex column and stored at 4 ⁰C. For NR delivery experiments 
empty liposomes were prepared with DOPG - Cholesterol combination and NR was 
incorporated into liposomes after preparation. 
49 
 
2.2.3.2 Characterization of Liposomes 
Particle size and Zeta-Potential by Dynamic Light Scattering:  
The mean diameter and zeta potential of liposomes were measured using a Malvern 
Zetasizer nano-ZS ZEN 3600 (Malvern Instruments, USA) instrument with detector angle 
of 173⁰. Standard deviations were calculated from the mean of the data of a series of 
experiments (n ≥ 3). Zeta measurement was carried out using a dip cell 35 electrode in 
quartz cuvettes.  
 
Transmission Electron Microscopy:  
Using a glass pipette, a drop of sample was added to a 200 mesh copper grid with a thin 
film of formvar polymer and carefully dried using a filter paper. Then, sample was left at 
room temperature to dry until a dried film was obtained. Transmission Electron 
Microscopy (TEM) analyses were performed using with FEI Tecnai G2 F30 operated at  
100 keV. 
 
Nile Red Polarization Studies:  
A 1.5 mM stock solution of Nile Red was prepared in ethanol and further diluted in water 
to 0.01 mM. Nile Red fluorescence intensity maxima switches with respect to the polarity 
of the environment and thus Nile Red dye solubility in different types of liposomes was 
measured and compared in between the formulations w/o peptide amphiphile. For this, 
final concentration of 3 μM, Nile Red was introduced in the liposome dispersions by 
injection of accurate amount of stock solution (450 μL) into 1.050 mL of 2x diluted 
liposome (2.5 mg/mL) or PBS. Samples were left to equilibrate for 24 h at 4 ⁰ C before 
measurements were taken. To determine micelle character, fluorescence intensity of 
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liposomes in PBS (λ excitation = 520 nm, λ emission = 525-700 nm) was measured and 
compared.  
 
Quantification of the number of membrane integrated peptide amphiphiles:  
Protein concentration determination procedure provided by Thermo Scientific was 
followed measuring the absorbance at analysis wavelength of 205 nm with extinction 
coefficient of 31 mg/mL at 1 cm path length. For this, peptide amphiphile solutions were 
prepared at different concentrations in the range of 0.6 mg/mL to 0 mg/mL by 2 fold 
dilution. Liposomes were purified from unbound peptide amphiphiles using Millipore 
Microcon Centrifugal Filter Units, with 50K MW cut-off, 3 to 4 times. Further, the waste 
was collected in each step and peptide concentration was measured via Thermo Scientific 
NanoDrop 2000. Peptide amphiphile integrated liposome concentration was then 
calculated indirectly by substituting the amount of unbound PA from initial PA. This 
information was later used for calculation of number of lipids per liposome.  
 
Determining encapsulation capacities of liposomes:  
A- Hydrophilic molecules: Rhodamine B (RHB) was used as tracker dye as model 
hydrophilic molecule and encapsulated at two initial concentrations of 10 μM and 100 μM 
using previously described liposome preparation procedure. Then, liposomes were 
purified from unbound RHB by using Centrifugal Filter Units with 50 kDa cut-off, 4 
times. RHB concentration was determined by fluorescence measurements (λ excitation= 
540 nm, λ emission= 575 nm) following the destruction of liposome integrity by use of 
EtOH (100 μL in 1900 μL EtOH) and % encapsulated RHB concentration was then 
calculated from previously prepared standard curve. Same procedure was followed for 
hydrophilic drug Doxorubicin HCl which was encapsulated with an initial concentration 
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of 0.2 mg/mL. Standard curve was obtained by using λ excitation of 480 nm and λ 
emission of 588 nm to measure fluorescence intensities of DOX with known 
concentrations. 
 
B- Hydrophobic molecules: NR was used as tracker dye as model hydrophobic drug. Dye 
encapsulation was tracked by measuring the increased emission (λ excitation = 476 nm, λ 
emission = 633 nm) following the administration of 0.53 μM NR to previously prepared 
liposomes. After 24 h, all samples reached to a maximum. At that point, liposomes were 
lysed by suspending 100 μL of sample in 1900 μL ethanol and encapsulated NR 
concentration was calculated by substituting the value of measured fluorescence to the 
standard curve. For hydrophobic drug, PTX, HPLC procedure optimized by Wang et 
al.[87] was used to measure encapsulation capacities and efficiencies of liposome 
formulations. PTX was extracted from the liposomes with acetonitrile (100 μL of 
liposome in 900 μL ACN), then filtered with a 0.2 mm syringe filter and the 
concentrations were analyzed using HPLC-1200S (Agilent). 10 μL sample solution was 
injected into Eclipse XDB-C18 (4.6 x 150 mm, 5 μm) column, water and acetonitrile in 
the volume ratio of 53:47 was used as mobile phase. Elution rate was 1.0 mL/min and the 
PTX detection wavelength was set at 229 nm. The drug concentration of PTX was 
calculated from standard curves.  
 
2.2.4 Cell Culture 
2.2.4.1 Cytotoxicity Tests 
Cytotoxicity of samples was evaluated using Alamar BlueTM assay. MCF7 cells were 
seeded in DMEM supplemented with 10% FBS and 1% Pen/Strep under conditions of 5% 
CO2 at 37 ⁰C. They were cultured in 96-well plate in 200 μL medium per well with a 
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density of 8000 cells/well for 24 h. 50 μL of liposome or peptide formulations were 
administered with final peptide concentrations of 250 μM, 25 μM and 12.5 μM in culture 
(n=4 for all groups). After 4 and 24 h incubation with liposomes, culture media replaced 
with serum free DMEM supplemented with %1 pen/strep and %10 Alamar BlueTM 
solutions and cells were incubated for additional 4 h. Cell viability was quantified 
spectrophotometrically by measuring fluorescence at excitation of 540 nm and emission of 
590 nm with microplate reader (Molecular Devices Spectramax M5). The data exhibited 
percentages of viable cells compared to the survival of a control group (1X PBS treated 
cells as controls of 100% viability). 
 
Cytotoxicity of anticancer agents was determined via a similar manner. MCF7 cells were 
plated in 96-well plates at a cell density of 8000 (for DOX treatment) and 4000 (for PTX 
treatment). Then, the cells were treated with serial dilutions of drug loaded liposomes and 
free drug for another 24 h. After rinsing the cells with fresh media, viability of cells were 
quantified via Alamar BlueTM assay as described previously. For time response 
experiments, cells were exposed to drug loaded liposomes and free drug, of which the 
final drug concentrations were adjusted to 10 μM for DOX and 30 μM for PTX, for 1, 3 
and 6 h. Afterwards cells were rinsed 2 times with fresh medium and incubated in 
standard cell culture medium for 24 h. Finally, cytotoxicity levels and inhibition of the 
cell proliferation were determined by Alamar Blue assay. 
 
2.2.4.2 Liposome Uptake Quantification 
MCF7 cells were seeded at a density of 30.000 cells per well in 24 well plates. 100 μL  of 
liposome formulations were then administered and 500 μL of total culture volume 
achieved. For RHB loaded liposomes, administration was optimized to a final RHB 
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concentration of 4.5 μM. After 3 h of incubation, culture media was removed and cells 
were washed 2 times with pre-warmed PBS. Afterwards, cells were lysed using 100 μL of 
0.5 M NaOH for 15 min with vigorous shaking in dark. Lysates were collected and 
centrifuged at 15000 rpm for 5 min. Rhodamine B concentration was measured from 
supernatants by fluorescence measurement by Nanodrop 3300 (Ex. 540 nm, Em. 590 nm).  
Measured fluorescence values were then normalized to protein concentrations of samples 
in order to calculate relative uptake score. Protein concentration of lysates was measured 
through Bradford protein assay (Roche). In the case of Nile Red (NR) loaded liposomes, 
sample concentrations were adjusted to obtain 10 μM of final NR concentration. After 3 h 
of incubation with either NR loaded liposomes or free NR, cells were cleaned as stated 
above and lysed with 300 μL of 90 % ethanol for 15 min with vigorous shaking. 
Afterwards, lysates were centrifuged and fluorescence of supernatants was measured at 
excitation/emission maxima of 476/633 nm.  Measured fluorescence units were used to 
estimate the relative uptake of liposomes loaded with NR. 
 
2.2.2.4 Imaging  
MCF7 cells were seeded at a density of 10.000 cells per well in 24 well plates with 1.5 
mm glass sphere. 100 μL of sample solution was administered with a final NR 
concentration of 10 μM. Final culture volume of 500 μL achieved. Following 24 h 
incubation, cells were washed two times in pre-warmed PBS and directly mounted onto 
glass slides. 20X and 40X images were taken by Zeiss AxioCamTM fluorescence 
microscope. All imaging parameters were same for all experimental groups. 
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2.3 RESULTS & DISCUSSION 
2.3.1 Synthesis and Characterization of Peptides and Liposomes 
2.3.1.1 Peptides  
Liposome functionalizations with cell penetrating peptides have been previously achieved 
through chemical conjugation of a peptide to the lipids before or after liposome 
preparation. Both strategies not only require additional steps and decrease the peptide 
integration efficiency but might also result in the loss of biological activity.[88] Prolonged 
steps of modification reactions and purification processes severely decrease the end yield 
of the final product as well. Thus, development of noncovalent strategies is preferred to 
avoid chemical modifications and subsequent extra procedures with low fidelity.[89] Use 
of amphiphilic peptides is a promising approach due to their chemical resemblance to 
phospholipids.[90-91] Therefore, we designed and synthesized an arginine-rich CPP 
amphiphile molecule consisting of a lauryl hydrocarbon chain group (C12), linker domain 
of poly proline and cell penetrating poly arginine domain, which gave rise to C12-
PPPPRRRR-NH2, as shown in figure 3. 
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Figure 3 Chemical representation of C12 (Lauryl)-PPPPRRRR-NH2, cell penetrating peptide 
amphiphile. Peptide consists of 3 main domains. C12 forms hydrophobic domain and 
facilitates incorporation with bilayer. Poly-Proline at linker domain prevents β-sheet 
formation and allows Poly-Arginine tip to reach bilayer surface. Poly-Arginine sequence at 
cell penetrating domain improves internalization and endosomal escape. 
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As mentioned in the materials and methods section, C12-PPPPRRRR-Am peptide 
amphiphile was constructed on MHBA Rink Amide resin which contains Fmoc protected 
amine groups. Fmoc protections were removed via 20% piperidine/DMF solution at each 
step. Subsequent to Fmoc deprotection, amino acid couplings were performed with Fmoc 
protected amino acid, HBTU and DIEA in DMF. After amino acid coupling, any possible 
unprotected amine groups were acetylated with %10 acetic anhydrate in DMF to block 
further elongation form these residues. This cycle including Fmoc deprotection, amino 
acid coupling and acetylation process was repeated with desired amino acids or C12 until 
all synthesis was completed. At the end of synthesis, we obtained amphiphilic peptides 
attached to Rink Amide resin. Cleavage of the peptides from resin was carried out with a 
mixture of TFA:TIS:H2O which breaks bonds between amide and the resin. Excess TFA 
was removed by rotary evaporation since overexposure to TFA may result damage on 
peptide. The remaining viscous peptide solution was treated with ice-cold diethyl ether 
and the resulting white pellet of peptides was obtained while small molecules and 
byproducts dissolved in ether. Acquired pellet was dissolved in water and freeze dried for 
further purification from organic solvents. Then we purified peptide by HPLC and 
analyzed the purity of peptide via LC-MS and liquid chromatography. As the liquid 
chromatogram below (Figure 4A) demonstrates, there is only one major product peak, 
which means only one type of material exists in sample solution.  
 
Subsequent to observing single peak, we analyzed sample with LC-MS in order to ensure 
the peak is belongs to C12-PPPPRRRR-NH2. Observed mass spectra ensured the purity of 
the peptide. As shown in spectra below, no contamination was observed. (Figure 4B)   
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Figure 4 A. Liquid chromatogram of Lauryl-PPPPRRRR-NH2. B. Mass spectrum of 
corresponding peptide molecule. Mass data [M+H]+ (calculated) = 1212.54, [M+H]+ 
(observed) = 1212.82 (observed [(M+2H)/2]+= 606.91, [(M+3H)/3]+= 404.94, [(M+4H)/4]+= 
303.96) 
 
 
 
A 
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2.3.1.2 Liposomes 
Cell penetrating arginine-rich peptide amphiphile integrated and bare liposomes were 
prepared according to curvature tuned liposome preparation (CTLP) method, where 
phospholipid residues are forced to be ordered in a nanostructure with the synergistic 
effect of a sudden pH jump and constant temperature.[86] By using this method, it is 
possible to integrate amphiphilic CPPs on liposome membrane via a single step and 
without any covalent reaction taking place. Addition of an amphiphilic molecule to 
liposomal membrane can change the fluidity and curvature of the membrane, as well as 
the physical properties of the resulting liposome such as particle size, zeta potential and 
morphology. In this study, negatively charged phospholipids, DOPG, was used as the 
main component of the liposomes.[92] Previously, it was observed that DOPG liposomes 
prepared by CTLP methodology with a size of 20 nm in diameter were not large enough to 
develop an efficient drug delivery system.[93-94] Therefore, cholesterol was incorporated 
into the formulation to reduce the membrane curvature, which resulted in formation of 
larger liposomes and provided intermediate membrane fluidity and prolonged circulation 
time due to delayed renal filtering.[95] As shown in Table 1, we obtained uniform 
liposomes with a size of 63.5±8.2 nm in diameter and a net negative charge of -41.4±3.9 
mV when liposomes were formed by DOPG and cholesterol at a molar ratio of 50:50. 
After peptide amphiphile integration, whether low or high amount of peptide was 
integrated, particle sizes of liposomes were measured to be 95.26±7.03 nm and 
measurements revealed that disparity between liposomes were quite trivial, so that only 
observed standard deviations were low. 
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Table 1 Physical properties of liposomes 
Liposome Formulation Size (nm) Zeta-Potential (mV) Peptide Integration % Peptide # per Liposome 
DOPG:Chol 63.5±8.2 -41.4±3.9 - - 
DOPG:Chol:PA* 95.26±7.03 -30.4±2.57 75.4 4568 
DOPG:Chol:PA* (Low) 98.49±4.9 -33.2±1.71 77.24 2706 
*Difference between DOPG:Chol:PA and DOPG:Chol:PA(Low) is amount of CPPA integrated. Ratios were 7:6:1 for first one while 
7:6.5:0.5 for DOPG:Chol:PA low. 
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In addition to size measurements, we sought to understand the change in electrical charge 
of liposomes upon PA modification. Zeta-potential of membrane, which mainly consist of 
negatively charged DOPG and neutral cholesterol, increased to -30.4 mV from -41.4 mV 
due to positive net charge possessed by the poly-arginine region of CPP amphiphile 
molecule. 
 
In order to further characterize physical characteristics of our liposomes, we conducted 
transmission electron microscopy imaging (Figure 5). Our main purpose with this imaging 
was to understand whether our liposomes were unilamellar or not. This is important since 
bilayer amount per liposome is a crucial parameter on cargo capacity.  Acquired images 
revealed that resulting liposomes were unilamellar in both PA modified and non modified 
groups. In addition to liposome lamellarity, observed sizes of liposomes were consistent 
with Zeta-sizer measurements which were around 50 nm for non modified ones versus 100 
nm for PA modified liposomes. Particle size of the liposomes stored at 4 °C was 
monitored, and no significant change was observed in samples for over 3 weeks. 
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Figure 5 Transmission electron microscope images of liposomes. A & C. DOPG:Chol, B & 
D. DOPG:Chol:PA. C & D are close section of single liposomes and red arrows point the 
unilamellar membrane. Scale bars = 10 nm, 50 nm and 100 nm, respectively. 
 
.  
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The amount of the peptide molecules incorporated into the liposomal membrane was 
calculated by measuring absorbance of free peptide molecules collected during the 
purification process.[91] As shown in Table 1 previously, about four thousand peptide 
amphiphile molecules were estimated to be integrated per liposome. Peptide amphiphile 
insertion was also monitored by fluorescence assay by using Nile Red as a polarity 
sensitive probe.[96] Nile Red dispersion is usually colorless in aqueous conditions, 
however, changes in the environment of the hydrophobic dye revealed a switch from polar 
to nonpolar in the presence of phospholipid and caused increased fluorescence emission. 
In the case of peptide-integrated liposomes, a blue shift was observed indicating a slight 
decrease in membrane polarity, indicating that the amphiphilic CPPs were integrated into 
membrane (Figure 6).  
 
Along with size and zeta-potential results, Nile Red polarity studies also confirmed that 
peptide amphiphile molecules were embedded into the liposomal membrane, and 
increased the nonpolar character of the membrane, which can be considered as an 
advantage for encapsulation of hydrophobic molecules. 
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Figure 6 Polarity change in DOPG:Chol liposomes from polar towards nonpolar when 
positively charged cell penetrating peptide amphiphiles were integrated to their membrane. 
Black DOPG:Chol liposomes. Red DOPG:Chol:PA liposomes. 
 
 
 
 
 
 
 
 
64 
 
2.3.2 Safety of Liposomal Carriers 
In order to evaluate the biocompatibility of liposomal formulations, MCF7 cells were treated 
with bare liposomes, PA integrated liposomes and PA molecules. Peptide amphiphiles 
molecules did not cause significant change in cell viability in either liposomal or free form 
after 4 h and 24 h of treatment (Figure 7A&B).  
 
On the contrary, liposomal formulations had trivial but positive effect on cell proliferation 
after 24 h, which could be due to use of liposomes as nutritional source by cells. Providing 
empty liposomes into culture media may enhance the fitness of cells within cell culture 
medium since cells were provided with readily available lipids and can build up more 
membranes (and eventually new cells) with fewer burdens on lipid biosynthetic pathways. 
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Figure 7 Viability of MCF7 cells after treatment with drug free liposomes with PA, without 
PA and only PA in free form for A. 4 h and B. 24 h.  Samples were optimized to final peptide 
concentrations of 250 (green), 25 (blue) and 12.5 (red) µM. Results were normalized to 
untreated cells in PBS. (n=4) 
 
A 
B 
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2.3.3 Enhanced Uptake via CPP Modification 
2.3.3.1 Liposomes with Hydrophilic Content 
Rhodamine B (RHB), a hydrophilic fluorescent dye, was used to probe uptake of 
liposomes prepared with and without peptide amphiphile molecules . Since it is 
fluorescently active and non toxic, we used RHB to track liposome internalization and 
cargo delivery dynamics. RHB was loaded into liposome during synthesis phase by adding 
into solution that will eventually form the whole liposome. Since it is hydrophilic, RHB 
cannot be loaded into lipid bilayer after liposomes were formed. After preparation, we 
observed that initial RHB concentration as well as peptide integration affected 
encapsulation capacities of the liposomes. Although encapsulated dye concentration 
decreased slightly from 36.3 mM to 30.5 mM after PA integration, they encapsulated 
almost four times higher amount of Rhodamine B compared to PA free liposomes (Table 
2). Since peptide modified liposomes have approximately two fold greater diameters 
(Table 1), which will eventually make them have approximately four times larger internal 
volume. Therefore peptide modified liposomes can entrap much more RHB. As shown in 
table 2, RHB per liposome is around four times greater when compared to non modified 
ones. 
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Table 2 Encapsulation of model dyes  
 
Encapsulated Rhodamine B (μM) Number of Rhodamine B Molecule / Liposome 
Liposome Formulation 10 μM* 100 μM* 10 μM* 100 μM* 
DOPG:Chol 7.90±0.8 36.3±3.9 4.15 x104 19.1x104 
DOPG:Chol:PA 7.00±0.4 30.5±2.2 12.4 x104 54x104 
*Represents initial concentration of Rhodamine B in environment where liposomes were synthesized. As mentioned in methods section, 
Rhodamine B was loaded into liposome during production phase. Therefore initial concentration of Rhodamine B is an important parameter 
defining the amount of cargo loaded into liposome.  
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Delivery efficiency of liposomes was evaluated via measuring the amount of fluorescent 
reagents uptaken by MCF7 cells. Tracking RHB uptake is an efficient way to quantify 
liposomal uptake rates.[97-98] Upon 3 h of treatment of equal amounts of RHB either with 
PA modified liposome, bare liposome or free form, use of PA integrated liposomes resulted in 
five folds more Rhodamine B uptake compared to both native liposomes and free RHB (p < 
0.001) (Figure 8). Although amount of dye encapsulated via peptide modified liposomes were 
larger, observed relative uptake increase was not caused by enhanced dye entrapment, since 
cells were treated with equal amount of RHB in every form. Therefore amount of peptide 
modified liposomes were quite few and these few liposomes performed very well in terms of 
cargo delivery. 
 
Additionally, although it was previously published that vehicle size and in vitro uptake rates 
are inversely proportional[99], we observed that cell penetrating PA integrated liposomes, 
which were larger than bare liposomes, showed enhanced delivery of hydrophilic dye into 
MCF7 cells. On the other hand, no significant difference was detected between uptake of free 
RHB and bare liposomes. These results revealed that noncovalent integration of cell 
penetrating PAs to liposomes improved cellular uptake of hydrophilic cargo by facilitating the 
liposome internalization rate. Cationic guanidine group of arginine side chain was previously 
shown to be important for the membrane translocation property[100], which might have 
enhanced internalization of PA functionalized liposomes.  
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Figure 8 Uptake of 4.5 µM Rhodamine B within DOPG:Chol and DOPG:Chol:PA liposomes 
by MCF7 breast cancer cells after 3 h of treatment. Free Rhodamine B was used as control. 
Acquired signals were normalized to protein concentration of samples to calculate relative 
uptake value.  (*** stands for p < 0.001) (n=4) 
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2.3.3.2 Liposomes with Hydrophobic Content 
Nile Red (NR) was used as a hydrophobic model molecule to observe uptake of PA integrated 
and bare liposomes. The hydrophobic dye encapsulation was performed after liposomes were 
prepared. Since NR is a hydrophobic dye and tends to interact with lipids rather than 
dissolving in aqueous environment. Hydrophobic dye hardly dissolved in water and liposomes 
provide a suitable environment for NR dye to embark. After loading process, in order to 
analyze amounts of loaded NR, free NR was firstly removed and encapsulated material was 
quantified by fluorescence spectroscopy along with calibration curve, after destruction of 
liposomes in ethanol. Due to slightly lower polarity and larger lipophilic surface area, 
amphiphilic peptide integrated liposomes entrapped four times higher amount of NR with 
respect to the bare liposomes (Table 3).  
 
The number of encapsulated dye per liposome was found to be 7.9 x 105 and 3.13 x 106 for 
bare and peptide integrated liposomes, respectively. Since modified liposomes have larger 
diameter and eventually much more lipids on bilayer structure, it was expected for CPP 
modified liposomes would have higher NR carriage capacity. 
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Table 3 Encapsulation of tracking dyes by liposomes 
Liposome Formulations Encapsulated Nile Red (μM) Number of Nile Red Molecule/ Liposome 
DOPG:Chol 150.4±5.2 7.90 x105 
DOPG:Chol:PA 176.7±6.7 31.3 x105 
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Several anticancer drugs including Paclitaxel (PTX), Cyclosporine, and Amphotericin B have 
hydrophobic properties and are absorbed in the membrane of liposome in addition to its 
lumen.[101] Therefore, NR is a hydrophobic fluorescent dye and is a suitable model molecule 
to track the behavior of the lipophilic cargo in liposomes. In order to track uptake efficiency 
of liposomes MCF7 cells were treated with free NR or native or PA integrated liposomes for 
3 h. Liposomes and dyes, which were not uptaken by cells, were removed via several washing 
steps. Then fluorescent images were taken with equal imaging parameters such as exposure 
time and gain. Fluorescent images indicated that hydrophobic cargo delivery rates of 
DOPG:Chol liposomes were slightly improved upon peptide modification in contrast to 
unmodified liposome. (Figure 9) In order to observe dose dependent improvement facilitated 
by peptide modification, we also used two different modified liposomes that bears different 
amount of peptides. Images also indicated that liposomes modified with high amount of 
amphiphilic CPP performed slightly better than liposomes modified with relatively low 
amount of amphiphilic cell penetrating peptides.   
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Figure 9 Uptake of 10 µM Nile Red by MCF7 cells. NR was administrated in free or 
liposome encapsulated form for 3 h. Fluorescent microscopy images of cells following 
liposomal DOPG:Chol:PA, DOPG:Chol:PA (Low), DOPG:Chol, and free Nile Red 
administration. 
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In addition to fluorescent images we also quantified amounts of dye internalized after 3 h of 
treatments. Uptake levels were quantified by NR extraction method, where non internalized 
liposomes were washed away and cells were lysed with ethanol. Since ethanol provide 
appropriate polar environment, Nile red dye becomes fluorescently active and can be 
measured with fluorescence spectroscopy. Quantification analysis revealed that PA integrated 
DOPG:Chol liposomes demonstrated enhanced uptake compared to bare liposomes (Figure 
10).   
 
Difference between liposomes with high and low amounts of CPP modification was also 
observed here. Uptake level of free Nile Red was significantly lower than that of both PA 
modified and bare liposomes. Uptake levels of each group were significantly different from 
each other, consistent with uptake images shown above. Considering the number of NR per 
liposome values, higher encapsulation capacity of PA integrated liposomes enables 
administration of less amount of liposome compared to bare liposomes for delivering equal 
concentration of Nile Red (Table 3). Thus, our results suggested that PA integration enhanced 
the hydrophobic Nile Red uptake not only by increasing the encapsulation capacity of 
DOPG:Chol liposomes but also by enhancing liposome internalization. 
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Figure 10 Uptake quantification of 10 µM Nile Red by MCF7 cells. NR was administered in 
free or liposome encapsulated form for 3 h. DOPG:Chol:PA and DOPG:Chol:PA(Low) 
differs in terms of amount of CPP incorporated.  Uptake levels quantified via ethanol lysis 
method prior to fluorescence spectroscopy. 
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2.3.3 Release Dynamics of Liposomes 
To understand the effect of PA integration on in vitro release of the entrapped Rhodamine 
B, liposomes suspended in 10% FBS containing PBS medium were dialyzed at pH 5.5 and 
pH 7.4 against PBS at 37 °C. The rationale underlying use of different pH s is to mimic 
different environments within body. pH 7.4 represents the blood circulation and 
extracellular environment, where it is better for liposomes to keep their content. pH 5.5 
represents acidic intracellular environment that liposomes are expected to release their 
contents there.  As shown in figure 9, DOPG:Chol:PA liposomes were stable for over 72 h 
with no apparent release (< 2%), while DOPG:Chol liposomes released 7.5% of the 
encapsulated RHB. On the other hand, both modified and non modified liposome 
formulations released just above 15 % of their content at pH 5.5.  
 
These results indicated that both formulations showed stability at both pH conditions and 
in serum containing PBS medium. Yet around 20 % of NR was released when intracellular 
environment was mimicked. We hypothesize that further NR integration into cells from 
liposomes occurs via lysis and destruction of liposome within cell. Due to its 
hydrophobicity and low solubility in water, we did not measure the release dynamics of 
Nile Red loaded liposomes. 
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Figure 11 In vitro release profile of DOPG:Chol and DOPG:Chol:PA liposomes at pH 7.4 and pH 5.5. Both liposome formulations were stable 
at physiological condition while they both showed slow release slightly triggered by acidic pH. 
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2.3.4 Therapeutic Effects of CPP Modified Liposomes 
2.3.4.1 Encapsulation of Doxorubicin and Paclitaxel 
After observing the improvement in terms of uptake, the effect of arginine-rich cell 
penetrating peptide integration on liposomal delivery was investigated by using two well-
known cancer drugs, hydrophilic Doxorubicin-HCl (DOX) and hydrophobic Paclitaxel (PTX). 
For DOX and PTX encapsulations, 1:25 and 1:15 (w/w) liposomal content to drug ratio were 
used, respectively. Both liposome formulation and the liposome preparation methods are 
important parameters affecting the encapsulation capacity.[102-103] Therefore, effect of 
peptide integration on encapsulated DOX amount was determined by using fluorescence 
spectroscopy, and PTX carrying liposomes were analyzed by HPLC to quantify entrapment 
efficiency. Results are presented in Table 4 and Table 5.  
 
Doxorubicin is a hydrophilic anticancer drug that is commonly used as cancer therapeutics. 
Since it is highly toxic and highly diffusible, proper delivery is essential. When we loaded 
DOX into native and PA integrated liposomes, amounts encapsulated were 0.26 mM and 0.23 
mM, respectively. Since similar methods with Rhodamine B encapsulation were used, similar 
drug load per liposome was observed when we compared modified and non-modified 
liposomes. 
 
Paclitaxel is a well known hydrophobic drug, which is currently used as dissolved in 
50:50 (v/v) mixture of Cremophor® and ethanol. Drawbacks of current formulation, such 
as Cremophor® associated serious side effects and possible precipitation of PTX in 
aqueous media, requires development of new carrier systems with high encapsulation 
efficiency.[104] Similar to Nile Red encapsulation results, PA integrated liposomes 
showed higher encapsulation efficiency for PTX compared to bare liposomes.  
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Table 4 DOX encapsulation capacities  
Liposome Formulation Encapsulated DOX (mM) Dox # per Liposome Encapsulation Efficiency (%) 
DOPG:Chol 0.258± 2.6x10-4 1.36 x103 75.0 
DOPG:Chol:PA 0.227±1.2 x10-3 4.03 x103 65.9 
 
Table 5 PTX encapsulation capacities 
Liposome Formulation Encapsulated PTX (mM) PTX # per  Liposome Encapsulation Efficiency (%) 
DOPG:Chol 0.092 4.85 x105 49.33 
DOPG:Chol:PA 0.117 20.7 x105 62.6 
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Larger size and eventually larger membrane of PA integrated liposome membrane 
compared to bare liposomes might be the reason for enhanced encapsulation of PTX. The 
concentration of encapsulated Paclitaxel was found to be 92 µM in native liposomes and 
117 µM in PA integrated liposomes (Table 5). When the number of encapsulated 
molecules per liposome for each drug was calculated, the PA integrated liposomes showed 
superior encapsulation efficiency over bare liposomes, as table 4 and 5 demonstrates. 
 
2.3.4.2 Therapeutic Effects of Doxorubicin Loaded Liposomes 
In vitro therapeutic effects of anticancer drug loaded PA integrated and PA free DOPG:Chol 
liposomes were evaluated via cytotoxicity assays and determination of cell proliferation rates 
by using MCF7 breast cancer cell line. The activity of Doxorubicin-HCl on tumor cells is 
mainly mediated by oxidative DNA damage and topoisomerase II inhibition in the nucleus, 
which results in apoptosis.[105] Here, dose response of DOX loaded DOPG:Chol liposomes 
and free DOX were evaluated by quantification of total metabolic activity of MCF7 cells after 
24 h of exposure (Figure 12).  
 
Half maximal inhibitory concentration (IC50) values were calculated as 2.58 μM, 2.48 μM 
and 0.88 μM for DOX loaded DOPG:Chol, DOPG:Chol:PA liposomes and free drug. When 
used at low concentrations, liposomal DOX was previously shown to have lower toxicity 
compared to free form.[106] As we see from the graph, free doxorubicin performed better 
than liposomes within concentration ranges of 0.5 to 2.5 μM. This condition may seem 
contrary to results shown in Rhodamine B uptake (Figure 3) where free Rhodamine B uptake 
was significantly lower when compared to peptide modified liposomes. Yet, cytotoxicity is a 
combination of parameters much more than cellular uptake. Liposomal DOX system is taken 
into the cell by endocytosis and is slowly released to the cytoplasm, which results in increased 
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number of barriers and slower therapeutic effect in contrast to free DOX.[106-107] 
 
Figure 12 Dose response of MCF7 cells against free Doxorubicin-HCl and Doxorubicin-HCl  
loaded DOPG:Chol and DOPG:Chol:PA liposomes. After 24 h of exposure to Doxorubicin-
HCl, viability of cells was measured by Alamar Blue. Results were normalized to untreated 
cells in PBS. (*** stands for p < 0.001, ** stands for p < 0.01, * stands for p < 0.05) (n=4) 
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Even though its uptake is less, free doxorubicin is able to diffuse directly into cell, and 
therefore it can demonstrate cytotoxic effect earlier. This condition is also consistent with the 
release dynamics of liposomes as shown in figure 9. According to release data, liposomes 
released just 20 percent of cargo. Overall, these results showed that increasing the 
concentration of DOX enhanced the effectiveness of liposome-DOX systems.     
 
Following dose response studies, time dependent response of MCF7 cells to DOX treatment 
was evaluated at 1, 3 and 6 h exposure times (Figure 11). In this experiment, cells were 
treated with doxorubicin either in free or liposomal form for 1, 3 and 6 h, then incubated for 
24 h without drug. We aimed to understand the effect of drug entered within given time 
periods only. As demonstrated in figure 10, 24 h exposure to drugs may not allow to analyze 
cytotoxic differences between delivery systems, since system is saturated with drugs and 
cytotoxicity levels were close to maximum achievable. 
 
 As expected, for both free and liposomal DOX systems, viability decreased with increasing 
exposure time. After 1 h of treatment, we observed that PA modified DOPG:Chol liposomes 
and free DOX had almost two fold lower viability with respect to PA free DOPG:Chol 
liposomes (p < 0.001). Higher cytotoxicity of PA integrated liposomal Doxorubicin-HCl 
demonstrated improvement in delivery efficiency caused by arginine-rich cell penetrating 
peptide incorporation into native liposomes. Bare liposomes exhibited a dramatic decrease in 
cell viability when exposure time was increased from 1 h to 3 h (p < 0.001) while PA 
integrated liposomes and free DOX did not show any significant difference. However, at 6 h 
of treatment, there was significant decrease in cell viability for PA integrated liposomal and 
free DOX (p < 0.001 for DOPG:Chol:PA and p < 0.01 for free Doxorubicin-HCl) compared 
to earlier time points. Statistically significant cell viability decrease was also observed for PA 
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free liposomes (p < 0.05) after 6 h of drug exposure compared to earlier time points.  
 
Figure 13 Time response of MCF7 cells to 1, 3 and 6 h of 10 µM free or liposomal 
Doxorubicin-HCl  treatment. Following administration, cells were incubated in fresh media 
for further 24 h and viability of cells was measured. (*** stands for p < 0.001, ** stands for p 
< 0.01, * stands for p < 0.05) (n=4) 
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2.3.4.3 Therapeutic Effects of Paclitaxel Loaded Liposomes 
Paclitaxel was used as a hydrophobic drug to examine in vitro therapeutic effect of liposome 
encapsulated and free drug. PTX mainly acts as G2/M cell cycle inhibitor and impedes cell 
proliferation by inhibiting microtubule dynamics.[108] Therefore it acts slowly, since it 
causes cell cycle arrest not as direct as doxorubicin which intercalates with DNA and disrupts 
central dogma. We investigated responses of MCF7 cells against free and liposomal PTX in 
both time and dose dependent manners by determining cell proliferation inhibition and fitness 
of the MCF7 cell culture. Dose dependent cytotoxicity studies demonstrated that PA 
integrated liposomes resulted in enhanced therapeutic effect at all doses from 0.2 nM to 2 µM 
of PTX (p < 0.001) compared to free PTX (Figure 12). Superiority of peptide modified 
liposomes was clear almost in every concentrations of PTX we administered. 
 
As a result of 10 µM PTX administration with DOPG:Chol and DOPG:Chol:PA, viability of 
MCF7 cells was equally affected and decreased to about 50%. At this concentration, the 
inhibitory effect was two folds higher for both PA integrated and native liposomes than that of 
free PTX. The results revealed that both liposomes caused proliferation inhibition since 
average doubling time of MCF7 cells are 24 h and untreated cell number (control group) was 
doubled at given time.[109] These results show that enhanced cell growth inhibition via PA 
incorporated liposomes was observed for PTX treatment with various concentrations. In the 
case of free form, we did not observe consistent decrease in cell viability through increasing 
PTX concentration on treatment media. This condition is probably due to low solubility of 
PTX that is not capable of diffusing freely in the media beyond 200 nM. Of course it was 
possible to increase its solubility by using chemicals like DMF or DMSO, yet cytotoxic 
properties of these solvents are too significant to ignore. 
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Figure 14 Dose response of MCF7 cells against free Paclitaxel and Paclitaxel loaded 
DOPG:Chol and DOPG:Chol:PA liposomes within spectrum of concentrations ranging from 
0.2 nM to 10 µM final concentration. Subsequent to 24 h of exposure to Paclitaxel, viability 
of cells was measured. Cell proliferation in the presence of DOPG:Chol:PA liposomes was 
significantly lower (p < 0.001) than both DOPG:Chol liposome and free Paclitaxel at all 
Paclitaxel concentrations except 10 μM. At 10 μM Paclitaxel concentration, free Paclitaxel 
showed significantly lower effect compared to both DOPG:Chol and DOPG:Chol:PA 
liposomes (p < 0.001). (n=4) 
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In addition, response of MCF7 cells was evaluated by administering 30 µM of PTX at 1, 3 
and 6 h. 24 h of drug free incubation was done to observe the effect of drug internalized 
only in given time periods. Results demonstrate that, peptide modified liposomes 
performed better in terms of inhibiting MCF7 cell culture after longer periods of treatment 
as shown in figure 14.  
 
At longer liposomal PTX exposure, cell viability decreased by 25 percent in peptide 
integrated liposomes, while it did not change and remained at 75 percent in native 
liposomes. In the case of free Paclitaxel, therapeutic effect was not improved and the cell 
viability was close to native liposomes. Both native and PA modified liposomes had time 
dependent cytotoxic response. Cells treated with free paclitaxel did not respond to 
changing exposure time, probably due to low solubility. Overall, our results suggest that 
PA integrated liposomes provide a more efficient delivery method for Paclitaxel compared 
to PA-free liposomes and free drug.  
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Figure 15 Time response of MCF7 cells to 1, 3 and 6 h of 30 µM free or liposomal Paclitaxel 
exposure. Cytotoxic effects of Paclitaxel loaded DOPG:Chol and DOPG:Chol:PA liposomes. 
All results were normalized to viability level of nontreated cells.  (*** stands for p < 0.001, 
** stands for p < 0.01, * stands for p < 0.05) (n=4) 
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2.4 CONCLUSION & FUTURE PERSPECTIVES 
In summary, we detailed the development of a liposomal carrier system and its 
functionalization with cell penetrating arginine-rich peptide amphiphile molecules by the 
use of amphipathicity as an alternative functionalization method for chemical linkage. The 
resulting liposomes were found to be nontoxic in the absence of cargo and had high 
encapsulation capacities for both hydrophobic (Nile Red) and hydrophilic (Rhodamine B) 
dye models. We also showed that these liposomes had very slow in vitro release rates, 
which enable the sustained and prolonged exposure of a given target tissue to the drug 
cargo.  Fluorescence spectroscopy measurements indicated that the integration of cell 
penetrating peptide amphiphiles onto the liposome surface enhanced the uptake of both 
hydrophobic and hydrophilic model reagents by MCF7 breast cancer cells with respect to 
both native liposomes and free reagents. In order to analyze the therapeutic potency of 
these liposomes in the delivery of common cancer drugs, Doxorubicin-HCl and Paclitaxel 
were loaded into liposomes and studied in vitro. Cytotoxicities of the drug-liposome 
complex were observed to depend on drug concentration. Time response studies showed 
that cell penetrating PA incorporation into DOPG:Chol liposomes improved liposomal 
delivery and enhanced the therapeutic effect of both hydrophilic (Doxorubicin-HCl) and 
hydrophobic (Paclitaxel) anticancer agents on MCF7 breast cancer cells. By using of this 
noncovalent functionalization technique, peptide epitopes can be easily incorporated into 
liposomal systems in a single step without requiring any additional chemical reagents, and 
the loss of activity normally associated with such modification methods is minimized by 
avoiding anchorage.  
 
The use of cell penetrating peptide amphiphiles was the simplest type of modification, and 
only aimed to enhance basic drug uptake rates and the therapeutic effect. By utilizing this 
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method, we developed a simple production method to facilitate liposome synthesis and 
modification in a single step. By using this approach, many types of advanced liposome 
modifications can be utilized. As reviewed in the first section, a variety of materials, such 
as bioactive peptides and small molecules, were used to bestow tumor targeting and 
improved uptake capacities to liposomes. By utilizing this method, a variety of 
modifications with different characteristics can be utilized on the same delivery vector. As 
mentioned earlier, many types of cancer cells have high affinities to RGD peptide, due to 
the overexpression of various integrins. It follows that an amphiphilic peptide 
incorporating this sequence would be an efficient modification to augment liposomal 
tumor targeting capacities. Another potential application could be use of amphiphilic 
peptides conjugated with estrogen. Many cancer types overexpresses estrogen receptors , 
and therefore readilyprovide a distinctive targeting moiety. Liposomes modified with 
estrogen-PA would be efficient nanovesicles for these types of cancer. Many more 
examples can be provided. The fact that their sequences can be altered to suit specific 
applications, amphiphilic peptides is coveted as surface modification materials. It is 
possible to mimic a wide range of molecules by changing aminoacid sequences or 
attaching various functional groups to a base peptide sequence. By modifying a novel 
peptide with proper chemical groups, it is always possible to create new opportunities to 
improve cargo delivery or achieve high specific targeting efficiencies.  
 
Overall, our strategy offers a high yield and efficient liposome modification method by 
which liposomes can be modified easily and efficiently with bioactive amphiphilic 
peptides. However, to fully evaluate the efficiency of our strategy, the targeting capacities 
of liposomes modified with different amphiphilic peptides need to be studied. In vivo 
studies can then be performed with the appropriate cancer model(s).       
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